ClinicalTrials.gg
CompletedNCT03293992Updated Mar 31, 2020

A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7058584 Following 7 Days of Instillation of Eye Drops in Patients With Primary Open Angle Glaucoma or Ocular Hypertension

A Phase 1 interventional study of 0.01% RO7058584 and 0.1% RO7058584 in Glaucoma, Open-angle and Ocular Hypertension, sponsored by Hoffmann-La Roche. Completed at 8 sites in United States. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2020-03-31.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2017, 8 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 348 studies in Glaucoma, Open-Angle with a site in United States — 49 open to participants now, 67 under way, 5 of them phase 3. Glaucoma, Open-Angle · United States.

Enrollment
233rd of 279
27 · median 84
Started
2017
with 14 others
Phase 1
19 of 348
2 open now
Registered
191st of 348
by date

Among the 348 studies in Glaucoma, Open-Angle with a site in United States, this one is the 233rd largest by enrollment of the 279 interventional ones that give a count, is one of 15 that started in 2017, is one of 19 in phase 1, and was the 191st registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

49 of the 348 studies in Glaucoma, Open-Angle with a site in United States are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 348 studies in Glaucoma, Open-Angle with a site in United States, or all of them as a file.
02

Study summary

This is a Phase I, multi-center, randomized, adaptive, investigator/patient-masked, placebo-controlled, parallel multiple-ascending dose study (Part A) with an extension including up to two selected doses from Part A and latanoprost 0.005% as active comparator (Part B).

03

Conditions studied

  • Glaucoma, Open-angle
  • Ocular Hypertension
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 to 90 years of age inclusive, at the time of signing the form
  • Confirmed diagnosis of ocular hypertension (OHT) or primary open-angle glaucoma (POAG) in both eyes as determined by the investigator at screening
  • Treatment-naïve participants or participants who are able to safely stop their Intraocular pressure (IOP)-lowering medication(s) prior to randomization according to the required minimum
  • At baseline visit, IOP ≥ 24 millimeters of mercury (mmHg) in the morning (8:00 AM ± 1h) and ≥ 22 mmHg in the afternoon (2:00 PM ± 1h) measurement in the same eye and ≤ 34 mmHg at all timepoints in both eyes
  • Best corrected logarithm of the minimum angle of resolution (logMAR) visual acuity score of 0.7 or better in each eye as measured by Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity test at screening
  • Central corneal thickness (pachymetry) measurement 450 to 620 micrometers (μm) in both eyes at screening
  • Cup-to-disc ratio ≤ 0.8 (both eyes) at screening
  • Anterior chamber angle is open and non-occludable (both eyes) as confirmed by the investigator by gonioscopy examination at screening

Exclusion criteria

Exclusion Criteria:

  • Advanced visual field defects
  • Other forms of glaucoma than POAG or OHT
  • Any abnormality preventing reliable applanation tonometry
  • Any corneal scarring, haze or opacity
  • Uncooperativeness of the participant that restricts adequate examination of IOP, ocular fundus or anterior chamber
  • Any presence or history of uveitis or other history of any ocular inflammatory disease.
  • History or signs of penetrating ocular trauma
  • Risk of visual field or visual acuity worsening in either eye as a consequence of glaucoma progression or consequence of participation in the trial or any other ocular disease, according to the investigator's best judgment
  • History of any glaucoma surgery
  • History of refractive surgery
  • Any other intra-ocular surgery within six months of screening
  • Any active ocular disease requiring treatment.
  • Use of any listed prohibited medications
  • Current enrollment or past participation within the last 30 days before the screening visit in any other clinical study involving an study treatment or any other type of medical research
  • Any participant who is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff thereof, directly involved in the conduct of the protocol
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    0.01% RO7058584 or Matching Placebo

    Drug: 0.01% RO7058584 · Drug: Matching Placebo

  • Experimental
    0.1% RO7058584 or Matching Placebo

    Drug: 0.1% RO7058584 · Drug: Matching Placebo

  • Experimental
    1% RO7058584 or Matching Placebo

    Drug: 1% RO7058584 · Drug: Matching Placebo

  • Experimental
    RO7058584 and Latanoprost 0.005%

    Drug: 0.01% RO7058584 · Drug: 0.1% RO7058584 · Drug: 1% RO7058584 · Drug: Latanoprost 0.005%

Interventions

  • Drug0.01% RO7058584

    Once daily morning administration for 7 days

  • Drug0.1% RO7058584

    Once daily morning administration for 7 days

  • Drug1% RO7058584

    Once daily morning administration for 7 days

  • DrugMatching Placebo

    Once daily morning administration for 7 days

  • Once daily morning or evening dosing

06

What researchers measure

Primary outcomes

  1. Incidence, Severity, and Causal Relationship of Ocular and Systemic Adverse Events (AEs)

    An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

    Time frame: Up to 12 weeks

  2. Incidence of Abnormal Laboratory Findings

    Time frame: Up to 12 weeks

  3. Incidence of Blood Pressure Abnormalities

    Time frame: Up to 12 weeks

  4. Incidence of Pulse Rate Abnormalities

    Time frame: Up to 12 weeks

  5. Incidence of Electrocardiogram (ECG) Findings

    Time frame: Up to 12 weeks

  6. Change From Baseline in Mean Intraocular pressure (IOP) After 7 Days of Study Drug Administration

    IOP will be assessed by Goldman Applanation tonometry.

    Time frame: 7 days

Secondary outcomes

  1. Change From Baseline in Mean Intraocular pressure (IOP) at Matched Clock-Times After 7 Days of Study Drug Administration

    IOP will be assessed by Goldmann Applanation tonometry

    Time frame: 7 days

  2. Cmax of RO7058584

    Cmax is the maximum observed plasma concentration.

    Time frame: Up to Day 8

  3. Tmax of RO7058584

    Tmax is the time to maximum observed plasma concentration.

    Time frame: Up to Day 8

  4. Ctrough of RO7058584

    Ctrough is the concentration at the end of a dosing interval before the next dose administration.

    Time frame: Up to Day 8

  5. AUC0-24h of RO7058584

    AUC0-24h is the area under the plasma concentration versus time curve (AUC) from Time 0 to 24 h post-dose.

    Time frame: Up to Day 8

07

Study locations

8 sites
  • Arizona Eye Center
    Chandler, Arizona 85225, United States
  • Sall Research Medical Center
    Artesia, California 90701, United States
  • United Med Res Inst
    Inglewood, California 90301, United States
  • Eye research foundation
    Newport Beach, California 92663, United States
  • Rocky Mountain Lions Eye Inst
    Aurora, Colorado 80045, United States
  • Eye Care Centers Management, Inc. (Clayton Eye Center)
    Morrow, Georgia 30260, United States
  • Coastal Research Associates
    Roswell, Georgia 30076, United States
  • Texan Eye/Keystone Research
    Austin, Texas 78731, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Dec 2017, 2 months.

Of 17 phase 1 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 23. This study's 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2017
First posted
Sep 26, 2017
StartActual
Oct 10, 2017
Primary completionActual
Dec 15, 2017
CompletionActual
Dec 21, 2017
Last update
Mar 31, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03293992
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Sep 26, 2017
Start date
Oct 10, 2017
Primary completion
Dec 15, 2017
Completion
Dec 21, 2017
Last update
Mar 31, 2020

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion